|Drug Patent Number||Company||Drug Patent Title||Drug Patent Expiry||Activity Alert|
|These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US8946292||JAVELIN PHARMS INC||Formulations of low dose diclofenac and beta-cyclodextrin|| |
(3 years from now)
Dyloject is owned by Javelin Pharms Inc.
Dyloject contains Diclofenac Sodium.
Dyloject has a total of 1 drug patent out of which 0 drug patents have expired.
Dyloject was authorised for market use on 23 December, 2014.
Dyloject is available in solution;intravenous dosage forms.
Dyloject can be used as management of pain.
The generics of Dyloject are possible to be released after 22 March, 2027.
Market Authorisation Date: 23 December, 2014
Treatment: Management of pain
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic